Targets › STMN1
1 program from 1 company in 1 trial: 1 Phase 4; Oncology; next expected readout Dec 2033.
Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules. Prevents assembly and promotes disassembly of microtubules. (UniProt, P16949)
Open in Phaseline: the race on STMN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Haukeland University Hospital | Biomarker guided weekly taxane treatment Stathmin-guided taxane chemotherapy based on tissue biomarker analysis | STMN1 | Phase 4 | Endometrial Cancer | Dec 2033 |
Endometrial Cancer (1)
small molecule (1)
Haukeland University Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.